10-Q: ARS Pharma Q3 2025: neffy Sales Surge, Debt Secured, Losses Mount

ARS Pharmaceuticals reports a significant increase in neffy product revenue and secured a $100 million term loan, but also saw a substantial rise in net loss and operating expenses for Q3 2025.

Summary

• Net product revenue for neffy surged to $31.3 million for the three months ended September 30, 2025, compared to $0.6 million in the prior year period.
• Total revenue for the quarter reached $32.5 million, a substantial increase from $2.1 million in Q3 2024.
• The company secured a $100.0 million Term A Loan on September 29, 2025, as part of a new Credit Agreement providing up to $250.0 million in term loans.
• Selling, general and administrative expenses dramatically increased to $74.8 million for Q3 2025, up from $19.3 million in Q3 2024, driven by marketing and personnel costs for neffy's commercial launch.
• Net loss for the quarter widened to $51.2 million, compared to $19.1 million in Q3 2024.
• For the nine months ended September 30, 2025, net product revenue was $51.9 million, and total revenue was $56.2 million.
• The accumulated deficit grew to $253.3 million as of September 30, 2025.
• Cash, cash equivalents, and short-term investments totaled $288.2 million as of September 30, 2025, deemed sufficient for at least the next three years.
• neffy 2mg was FDA approved in August 2024 and launched commercially in September 2024, while neffy 1mg was FDA approved in March 2025 and launched in May 2025.
• EURneffy (2mg) received European Commission marketing authorization in August 2024 and launched in Germany in June 2025 and the UK in October 2025.
• neffy 2mg and 1mg were approved in Japan in September 2025, with commercial launch expected in Q4 2025.

Sentiment

Score: 4

Explanation: The company achieved significant revenue growth from neffy's commercial launch and expanded its global footprint. However, this growth came at a substantial cost, leading to a sharp increase in net loss and cash used in operations. The accumulated deficit continues to grow, and while current liquidity is projected to last three years, the company acknowledges the need for potential future capital raises and faces multiple legal and competitive risks.

Positives

• Product revenue for neffy increased significantly to $31.3 million for the three months and $51.9 million for the nine months ended September 30, 2025.
• Successful FDA approval and commercial launch of neffy 2mg (August/September 2024) and neffy 1mg (March/May 2025) in the United States.
• European Commission marketing authorization for EURneffy 2mg (August 2024) and subsequent launches in Germany (June 2025) and the UK (October 2025).
• Regulatory approval for neffy 2mg and 1mg in Japan (September 2025), with commercial launch anticipated in Q4 2025.
• Secured a $100.0 million Term A Loan, enhancing liquidity and providing access to up to $250.0 million in total term loans.
• Positive survey results from the neffy experience program showed approximately 90% of patients effectively treated with a single dose, comparable to epinephrine injection.
• Existing cash, cash equivalents, and short-term investments of $288.2 million are projected to be sufficient for at least the next three years.
• Expansion of sales force to 107 ARS Pharma employees and 70 ALK U.S. sales reps to drive commercialization.
• Initiation of a Phase 2b clinical trial for chronic spontaneous urticaria, with topline data anticipated in mid-2026.

Negatives

• Net loss significantly increased to $51.2 million for the three months ended September 30, 2025, from $19.1 million in the prior year.
• Accumulated deficit grew substantially to $253.3 million as of September 30, 2025, from $123.3 million at December 31, 2024.
• Selling, general and administrative expenses surged by $55.5 million for the quarter, primarily due to marketing and personnel costs, indicating high commercialization spend.
• Net cash used in operating activities increased significantly to $127.4 million for the nine months ended September 30, 2025, compared to $28.5 million in the prior year, indicating a higher cash burn.
• Total stockholders' equity decreased from $256.8 million at December 31, 2024, to $147.7 million at September 30, 2025.
• The company is highly dependent on the successful commercialization of neffy, and its business, financial condition, and stock price would be materially adversely affected if neffy is not commercially successful.
• The Credit Agreement contains restrictive covenants, including limitations on incurring additional debt and certain strategic transactions without lender consent, and a minimum liquidity covenant of $25.0 million.
• The Term C Loan of $25.0 million is subject to achieving trailing 12-month net revenues for neffy of at least $100.0 million, which may not be met.
• The company faces multiple legal proceedings, including patent infringement claims against Lupin and trade secret/breach of contract allegations from AptarGroup, which could be costly and divert resources.

Risks

• High dependence on the successful commercialization of neffy in the United States and EU; failure would materially adversely affect business and stock price.
• neffy may fail to achieve market acceptance by physicians, patients, caregivers, and third-party payors, hindering commercial success.
• Inability to achieve and maintain adequate levels of third-party payor coverage and reimbursement for neffy on reasonable pricing terms.
• Competitive products may reduce or eliminate the commercial opportunity for neffy or future intranasal epinephrine technology product candidates.
• Inability to successfully develop current or future intranasal epinephrine technology product candidates, or neffy for additional indications, or significant delays in doing so.
• FDA may not conclude that future product candidates or additional indications satisfy Section 505(b)(2) regulatory approval pathway requirements, leading to longer, costlier, and riskier approval processes.
• Product liability lawsuits against the company or partners could divert resources, incur substantial liabilities, and limit commercialization.
• Compromise of information technology systems or data could lead to regulatory investigations, litigation, fines, business disruptions, and reputational harm.
• Complete reliance on third parties to manufacture and warehouse domestic and international supply of neffy and product candidates.
• Dependence on international third-party licensees for development and commercialization outside the United States; their failure could adversely affect business.
• International trade policies, including tariffs, sanctions, and trade barriers, may adversely affect business, financial condition, results of operations, and prospects.
• Timing of sales and results of operations are expected to fluctuate, making future performance difficult to predict.
• Significant losses incurred since inception, with no assurance of future profitability.
• Need for additional funding; inability to raise capital when needed could force delays, reductions, or elimination of product development or commercialization efforts.
• Inability to obtain and maintain sufficient intellectual property protection for neffy and other proprietary technologies.
• Credit Agreement contains conditions and restrictions that limit flexibility and may require early repayment if an event of default occurs.
• Success is highly dependent on the ability to attract and retain highly skilled executive officers and employees.
• Results of early-stage clinical trials and preclinical studies may not be predictive of future results.
• Interim topline and preliminary data from clinical trials may change as more patient data become available.
• neffy or future product candidates may cause undesirable side effects or adverse events, leading to regulatory delays, restrictive labels, or market withdrawal.
• Fast Track or Priority Review designations may not lead to faster development or approval.
• FDA or other regulatory authorities may approve generic versions of neffy or not grant appropriate periods of non-patent exclusivity.
• Obtaining regulatory approval in one jurisdiction does not guarantee success in others.
• Ongoing obligations and continued regulatory review for neffy may result in significant additional expense, post-marketing restrictions, or market withdrawal.
• Recently enacted and future legislation (e.g., ACA, IRA, OBBBA) may increase difficulty and cost to commercialize neffy and affect pricing.
• Disruptions at the FDA, including workforce reductions or inadequate funding, could prevent normal functions.
• Foreign governments may impose strict price controls.
• Business activities may be subject to FCPA and similar anti-bribery/anti-corruption laws, U.S. and foreign export controls, trade sanctions, and import laws.
• Relationships with customers, healthcare professionals, and third-party payors may be subject to applicable healthcare laws (e.g., Anti-Kickback Statute, False Claims Act, HIPAA, Sunshine Act).
• Stringent and evolving U.S. and foreign laws, regulations, and obligations related to data privacy and security (e.g., CCPA, MHMD, GDPR, PIPL).
• Difficulties in managing growth, including expanding headcount and improving systems.
• Market price of common stock could be volatile.
• Delaware law and corporate provisions could make a merger, tender offer, or proxy contest difficult.
• Exclusive forum provisions could limit stockholders' ability to obtain a favorable judicial forum.
• Geo-political conditions (e.g., Russia-Ukraine, Middle East conflicts) may adversely affect business.
• Failure to maintain proper and effective internal controls could impair ability to produce accurate financial statements.

Future Outlook

Operating expenses are expected to increase for the foreseeable future, with no assurance of achieving or sustaining profitability. Product revenues are anticipated to fluctuate as the commercial launch of neffy continues, and collaboration revenues will depend on meeting regulatory and commercial milestones. Zero-cost inventory components are expected to be substantially consumed by mid-2026. Topline data from the Phase 2b chronic spontaneous urticaria clinical trial is anticipated in mid-2026, potentially followed by a pivotal efficacy study. Regulatory decisions for EURneffy 1mg (EMA), neffy in Canada, and neffy in China are expected in the first half of 2026, with commercial launches in Japan (Q4 2025) and Canada (H1 2026) also planned. Existing cash, cash equivalents, short-term investments, and revenues are projected to be sufficient for at least the next three years, but additional funding may be required if substantial product revenue is not generated.

Management Comments

• "neffy is the first and only FDA and European Commission-approved needle-free epinephrine product, and the first new delivery method for epinephrine in more than 35 years."
• "We believe the market opportunity for neffy in the United States alone is significant."
• "We believe neffy's no needle, no injection approach addresses a significant unmet need in the use of epinephrine..."
• "In aggregate, we estimate that up to 90% of patients prescribed an epinephrine device are not achieving an optimal treatment outcome today."
• "Our launch strategy for neffy in the United States involves direct outreach to high-volume prescribers of epinephrine accounting for approximately 55% of prescriptions in the last year through an efficient sales force."
• "neffy has been approved or is under regulatory review in countries representing approximately 98% of the current global epinephrine autoinjector sales."
• "Based on our current operating plan, we believe that our existing cash, cash equivalents, short-term investments, and revenues from product sales and cash proceeds from collaboration and out-licensing agreements will be sufficient to meet our anticipated cash requirements through at least the next three years."

Industry Context

ARS Pharma is disrupting the emergency epinephrine market, which has been dominated by injectable autoinjectors for over 35 years, with its needle-free intranasal neffy. This positions the company as an innovator addressing significant patient apprehension and administration issues associated with traditional devices. The market opportunity for epinephrine products is substantial, with 40 million people in the U.S. experiencing Type I allergic reactions and a significant portion of diagnosed patients not consistently carrying or filling prescriptions for existing autoinjectors. neffy aims to capture this unmet need. The company faces intense competition from established players like Viatris (EpiPen), Teva, Amneal (Adrenaclick), Kaleo (Auvi-Q), and Sandoz (Symjepi), as well as other companies developing intranasal or sublingual epinephrine candidates (Bryn Pharma, Nasus Pharma, Hikma, Orexo AB, Belhaven BioPharma, Aquestive Therapeutics). Global expansion through partnerships (ALK, Alfresa, Pediatrix, Seqirus) is a key strategy to penetrate international markets, which collectively represent a large portion of global epinephrine sales. The increasing scrutiny on drug pricing and reimbursement, along with evolving data privacy regulations and geopolitical trade policies, presents a challenging regulatory and economic environment for pharmaceutical companies.

Comparison to Industry Standards

• neffy is the first and only FDA and European Commission-approved needle-free epinephrine product, representing the first new delivery method in over 35 years, setting a new standard for convenience and potentially adherence compared to traditional autoinjectors like EpiPen, Adrenaclick, Auvi-Q, and Symjepi.
• Clinical data for neffy demonstrated blood levels comparable to approved injectable products and statistically significant pharmacodynamic responses, suggesting it meets efficacy benchmarks set by existing market leaders.
• The reported 90% effective treatment rate with a single dose in the neffy experience program is indistinguishable from historical rates for epinephrine injection, indicating competitive clinical performance.
• The company's market penetration strategy, including a direct sales force, co-promotion with ALK U.S. targeting pediatricians, and patient assistance programs like neffyconnect and neffy inSchools, aligns with aggressive launch strategies seen for novel pharmaceutical products, aiming to rapidly build brand awareness and market share against entrenched competitors.
• The global regulatory approvals and ongoing reviews in major markets (US, EU, Japan, Canada, China) for neffy demonstrate a broad market access strategy, comparable to leading pharmaceutical companies seeking to maximize global reach for key products.
• The significant increase in SG&A expenses, particularly marketing, is typical for a company launching a new, innovative product in a competitive market, aiming to rapidly build brand awareness and market share against entrenched competitors.

Legal Proceedings

• Aera A/S vs. ARS Pharmaceuticals, Inc. (EPO): Opposition filed July 24, 2023, regarding EP 3678649 patent (nasal spray formulation of epinephrine). Oral proceedings held October 7, 2025, where the Opposition Division upheld the validity of all claims. A written decision is expected within one to two months, with potential for appeal.
• AptarGroup, Inc. vs. ARS Pharmaceuticals, Inc. (US District Court for the Southern District of New York): Filed March 25, 2025, alleging violation of the Defend Trade Secrets Act, misappropriation of trade secrets under New York state law, and various breaches of contract. ARS Pharma filed a motion to dismiss on June 12, 2025, which Aptar opposed on July 28, 2025.
• ARS Pharmaceuticals, Inc. vs. AptarGroup, Inc. (U.S. District Court for the Southern District of California): Filed September 29, 2025, alleging AptarGroup violated federal antitrust law in connection with its sale of certain constituent parts of neffy.
• ARS Pharmaceuticals, Inc. vs. Lupin, Inc., Lupin Ltd., and Lupin Pharmaceuticals, Inc. (U.S. District Court for the District of New Jersey): Filed August 29, 2025, alleging infringement of U.S. Patent Nos.: 10,576,156, 10,682,414, 11,173,209, 11,191,838, 11,717,571, 11,744,895, 11,918,655, and 12,324,838. This follows a Paragraph IV certification notice from Lupin on August 13, 2025, seeking approval for a generic version of neffy 2mg. The lawsuit seeks a permanent injunction.

Related Party Transactions

• Consulting agreement with Pacific-Link Regulatory Consulting, Inc., an entity owned by the President/CEO/director and his spouse (CMO). Expenses: $0.6 million (Q3 2025), $1.9 million (9 months Sep 2025).
• Consulting agreement with Marlinspike Group, LLC, whose managing member is the Chair of the Board of Directors. Expenses: $0.1 million (Q3 2025), $0.2 million (9 months Sep 2025).
• Consulting agreement with a member of the Board of Directors for general advice and assistance. Stock-based compensation expense: zero (Q3 2025), less than $0.1 million (9 months Sep 2025).
• Credit Agreement (September 29, 2025) with RA Capital Agency Services, LLC (Administrative Agent and Collateral Agent) and affiliates of OMERS Administration Corporation and RA Capital Management, L.P. (Lenders). RA Capital affiliates collectively hold over 10% of outstanding common stock and are the largest stockholder. A board member is a controlling person of RA Capital's general partner. A RA Capital-affiliated Lender holds $5.0 million of the Term Loans.
• OrbiMed Advisors LLC (an affiliate of which a board member is a General Partner) purchased rights, royalty interests, and sales milestone payments from Aegis in November 2024. The company now makes payments to an OrbiMed affiliate. Royalty expense: $2.0 million (Q3 2025), $3.4 million (9 months Sep 2025). Sales-based milestone payment: $2.0 million (Q3 2025), $2.0 million (9 months Sep 2025).

Stakeholder Impact

• Shareholders: Potential for dilution from future equity offerings. Stock price volatility due to financial performance, regulatory decisions, competitive landscape, and legal proceedings. Value of common stock could be adversely affected by restrictive covenants in the Credit Agreement.
• Patients/Caregivers: Increased access to a needle-free epinephrine option (neffy) for Type I allergic reactions, potentially improving adherence and reducing apprehension. Ongoing clinical trials for additional indications like urticaria could offer new treatment options.
• Employees: Significant increase in headcount (from 23 to 162 full-time employees) indicates growth and job opportunities, but also challenges in managing rapid expansion. Stock-based compensation is a significant part of employee remuneration.
• Customers (Wholesale Distributors/Pharmacies): Direct sales model implemented in August 2025 means the company now retains all credit and collection risk, shifting from the Title Agent model.
• Partners (ALK, Alfresa, Pediatrix, Seqirus): Collaboration agreements are crucial for global commercialization and revenue generation, but performance depends on partners' efforts and compliance. ALK U.S. co-promotion involves base fees and performance-based bonuses.
• Creditors (Lenders under Credit Agreement): The company has secured $100.0 million in term loans, with assets pledged as collateral. Covenants and revenue requirements for future tranches impact the company's financial flexibility and ability to service debt.
• Suppliers (Renaissance, Ompi, raw material providers): Reliance on third-party manufacturers and suppliers for critical components and finished products. Unconditional purchase obligations ensure future demand but also represent commitments.

Next Steps

• EMA regulatory decision for EURneffy 1mg expected in the first half of 2026.
• Commercial launch of neffy in Japan expected to start in Q4 2025.
• Regulatory decisions for neffy in Canada anticipated in Q1 2026, with launch expected in H1 2026.
• Regulatory decisions for neffy in China anticipated in H1 2026.
• Topline data from Phase 2b chronic spontaneous urticaria clinical trial anticipated in mid-2026.
• Potential initiation of a single pivotal efficacy study for chronic spontaneous urticaria following Phase 2b data.
• Substantial consumption of zero-cost inventory components in commercial production by mid-2026.
• Expected issuance of a written decision from the EPO's Opposition Division within one to two months regarding the EP 649 Patent.
• Continued defense in the Aptar Litigation and prosecution of the antitrust lawsuit against AptarGroup.
• Vigorous defense of patents against Lupin's generic neffy 2mg ANDA.
• Continued efforts to obtain and maintain adequate third-party payor coverage and reimbursement for neffy.
• Ongoing evaluation of opportunities to in-license or acquire other development programs, product candidates, or commercial products.

Key Dates

Recommendation

While ARS Pharmaceuticals has achieved significant milestones with neffy's FDA and EC approvals and has seen a substantial increase in product revenue, the company is in a high-growth, high-spend phase. The net loss and cash burn have increased dramatically due to aggressive commercialization efforts and R&D. The accumulated deficit is substantial, and while current liquidity is projected for three years, future capital raises are explicitly mentioned as a possibility, which could lead to dilution. The company faces multiple legal challenges, including patent infringement and trade secret disputes, which introduce significant uncertainty and potential costs. The stock is likely to be volatile given these factors. A "hold" recommendation reflects the promising market opportunity and commercial progress of neffy, balanced against the significant financial losses, high operating expenses, reliance on future funding, and ongoing legal and competitive risks. Investors should monitor the trajectory of neffy sales, progress in legal proceedings, and the company's path to profitability.

Keywords

ARS Pharmaceuticals, neffy, Epinephrine Nasal Spray, Anaphylaxis Treatment, Needle-Free Epinephrine, Biopharmaceutical, SEC Filing, 10-Q Report, Financial Results, Commercialization, Drug Approval, FDA Approval, European Commission Approval, Clinical Trials, Intranasal Epinephrine, Allergy Treatment, Pharmaceutical Industry, Q3 2025 Earnings, Drug Development, Corporate Debt, Intellectual Property, Regulatory Affairs, Market Launch, ALK Collaboration, Lupin Lawsuit, AptarGroup Litigation, Urticaria